董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Jon Lieber | 男 | Independent Director | 57 | 11.08万美元 | 0.91 | 2026-07-23 |
| Jennifer Bath | 女 | Chief Executive Officer,President and Director | -- | 151.22万美元 | 102.54 | 2026-07-23 |
| Dirk Witters | 男 | Chair of the Board and Independent Director | -- | 10.61万美元 | 6.57 | 2026-07-23 |
| Jon Lieber | 男 | Independent Director | -- | 未披露 | 未持股 | 2026-07-23 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| R. Scott Areglado | 男 | Chief Financial Officer | 62 | 70.87万美元 | 2.65 | 2026-07-23 |
| Jennifer Bath | 女 | Chief Executive Officer,President and Director | -- | 151.22万美元 | 102.54 | 2026-07-23 |
| Kari Graber | 女 | Vice President of Commercial Services | -- | 48.56万美元 | 7.45 | 2026-07-23 |
| Thomas W. Lynch | 男 | Chief Business Officer | -- | 75.22万美元 | 4.10 | 2026-07-23 |
| Shuji Sato | 男 | Vice President of Innovative Solutions | -- | 31.56万美元 | 1.20 | 2026-07-23 |
董事简历
中英对照 | 中文 | 英文- Jon Lieber
-
根据与Danforth Advisors，LLC或Danforth的协议，Jon Lieber自2019年7月1日起担任我们的临时首席财务官，Danforth是一家专门与生命科学公司合作的金融咨询公司。自2018年12月以来，Lieber先生一直担任Danforth的董事总经理。在加入Danforth之前，Lieber先生于2015年6月至2018年12月担任Histogenics Corporation（现为Ocugen，Inc.）的首席财务官。2014年1月至2015年6月，Lieber先生担任Metamark Genetics，Inc.的高级副总裁兼首席财务官。他任职于SalariusPharmaceuticals，Inc.公司（一家专注于癌症的生物技术公司）的董事会。Lieber先生拥有波士顿大学（Boston University）工商管理学士学位和纽约大学斯特恩商学院（New York University Stern School of Business）金融学工商管理硕士学位。
Jon Lieber currently serves as Chief Financial Officer at Rallybio, a clinical stage biotechnology company developing therapies for severe and rare diseases.Prior to Rallybio, Mr. Lieber was CFO at Applied Genetic Technologies Corporation (AGTC), a publicly traded gene therapy company, where he led all capital raising efforts and oversaw finance, human resources, investor relations, and IT. He has also held senior leadership roles at Danforth Advisors, Histogenics, Repligen, Xcellerex (acquired by GE Healthcare), and Altus Pharmaceuticals. Earlier in his career, he worked in investment banking at Salomon Brothers / Salomon Smith Barney and SG Cowen. Mr. Lieber currently serves on the Board of Directors of Salarius Pharmaceuticals, where he is a member of both the Audit Committee and the Nominating and Governance Committee. - 根据与Danforth Advisors，LLC或Danforth的协议，Jon Lieber自2019年7月1日起担任我们的临时首席财务官，Danforth是一家专门与生命科学公司合作的金融咨询公司。自2018年12月以来，Lieber先生一直担任Danforth的董事总经理。在加入Danforth之前，Lieber先生于2015年6月至2018年12月担任Histogenics Corporation（现为Ocugen，Inc.）的首席财务官。2014年1月至2015年6月，Lieber先生担任Metamark Genetics，Inc.的高级副总裁兼首席财务官。他任职于SalariusPharmaceuticals，Inc.公司（一家专注于癌症的生物技术公司）的董事会。Lieber先生拥有波士顿大学（Boston University）工商管理学士学位和纽约大学斯特恩商学院（New York University Stern School of Business）金融学工商管理硕士学位。
- Jon Lieber currently serves as Chief Financial Officer at Rallybio, a clinical stage biotechnology company developing therapies for severe and rare diseases.Prior to Rallybio, Mr. Lieber was CFO at Applied Genetic Technologies Corporation (AGTC), a publicly traded gene therapy company, where he led all capital raising efforts and oversaw finance, human resources, investor relations, and IT. He has also held senior leadership roles at Danforth Advisors, Histogenics, Repligen, Xcellerex (acquired by GE Healthcare), and Altus Pharmaceuticals. Earlier in his career, he worked in investment banking at Salomon Brothers / Salomon Smith Barney and SG Cowen. Mr. Lieber currently serves on the Board of Directors of Salarius Pharmaceuticals, where he is a member of both the Audit Committee and the Nominating and Governance Committee.
- Jennifer Bath
-
詹妮弗·巴斯（Jennifer Bath），在生物制药行业拥有二十年的经验，此前曾在Aldevron，LLC的执行团队任职。此前，她是全球疫苗研究所的执行董事，曾担任国际顾问，在战略规划和企业增长以及将制药公司的科学挑战转化为运营解决方案方面拥有经验丰富且经过验证的领导者。巴斯博士专注于战略增长、业务运营调整和价值创造。她拥有北达科他州立大学细胞和分子生物学博士学位。
Jennifer Bath serves as President and Chief Executive Officer of MindWalk Holdings Corp. She holds a PhD in Cellular and Molecular Biology, with a specialization in immunology and biochemistry, and has built her career at the intersection of biological science, bioinformatics, and artificial intelligence. Prior to MindWalk, Dr. Bath held a tenured Associate Professorship and founded the Concordia Global Vaccine Institute, where she directed programs to discover and validate biologics for infectious diseases. She subsequently held executive roles across the biotechnology sectors, including an executive position at Aldevron, where she led global client relations and high value target teams, translating complex scientific and commercial challenges into operational strategy for pharmaceutical and biotech worldwide. At MindWalk, Dr. Bath leads the Company's scientific and technology teams in building its integrated discovery platform, which combines LensAI, powered by HYFT technology, with advanced wet lab capabilities. Under her leadership, the Company has advanced dozens of client molecules toward the clinic and launched ReefIQ. - 詹妮弗·巴斯（Jennifer Bath），在生物制药行业拥有二十年的经验，此前曾在Aldevron，LLC的执行团队任职。此前，她是全球疫苗研究所的执行董事，曾担任国际顾问，在战略规划和企业增长以及将制药公司的科学挑战转化为运营解决方案方面拥有经验丰富且经过验证的领导者。巴斯博士专注于战略增长、业务运营调整和价值创造。她拥有北达科他州立大学细胞和分子生物学博士学位。
- Jennifer Bath serves as President and Chief Executive Officer of MindWalk Holdings Corp. She holds a PhD in Cellular and Molecular Biology, with a specialization in immunology and biochemistry, and has built her career at the intersection of biological science, bioinformatics, and artificial intelligence. Prior to MindWalk, Dr. Bath held a tenured Associate Professorship and founded the Concordia Global Vaccine Institute, where she directed programs to discover and validate biologics for infectious diseases. She subsequently held executive roles across the biotechnology sectors, including an executive position at Aldevron, where she led global client relations and high value target teams, translating complex scientific and commercial challenges into operational strategy for pharmaceutical and biotech worldwide. At MindWalk, Dr. Bath leads the Company's scientific and technology teams in building its integrated discovery platform, which combines LensAI, powered by HYFT technology, with advanced wet lab capabilities. Under her leadership, the Company has advanced dozens of client molecules toward the clinic and launched ReefIQ.
- Dirk Witters
-
德克·维特斯（Dirk Witters）于2019年创立了Conanti Consult BV，这是一家咨询精品店，除其他外，他在该公司就收购和融资转让的执行提供建议。在此之前，Witters先生还曾在2019年7月至2020年3月期间担任私募股权投资公司New Rhein Healthcare Investors创始人的顾问。此外，Witters先生于2018年12月至2019年6月担任KBC集团可持续金融项目管理办公室主任；并于2020年6月至2022年4月担任BioStrand BV董事会主席。
Dirk Witters founded Conanti Consult BV in 2019, an advisory boutique, where he, among other things, advises on the execution of acquisitions and capital raising assignments. Prior to that, Mr. Witters also served as an advisor to the founder of New Rhein Healthcare Investors, a private equity investment firm from July 2019 to March 2020. In addition, Mr. Witters was the Director Program Management Office, Sustainable Finance for KBC Group from December 2018 to June 2019; and the president of the Board of BioStrand BV from June 2020 to April 2022. - 德克·维特斯（Dirk Witters）于2019年创立了Conanti Consult BV，这是一家咨询精品店，除其他外，他在该公司就收购和融资转让的执行提供建议。在此之前，Witters先生还曾在2019年7月至2020年3月期间担任私募股权投资公司New Rhein Healthcare Investors创始人的顾问。此外，Witters先生于2018年12月至2019年6月担任KBC集团可持续金融项目管理办公室主任；并于2020年6月至2022年4月担任BioStrand BV董事会主席。
- Dirk Witters founded Conanti Consult BV in 2019, an advisory boutique, where he, among other things, advises on the execution of acquisitions and capital raising assignments. Prior to that, Mr. Witters also served as an advisor to the founder of New Rhein Healthcare Investors, a private equity investment firm from July 2019 to March 2020. In addition, Mr. Witters was the Director Program Management Office, Sustainable Finance for KBC Group from December 2018 to June 2019; and the president of the Board of BioStrand BV from June 2020 to April 2022.
- Jon Lieber
-
Jon Lieber目前在Rallybio担任首席财务官，这是一家临床阶段的生物技术公司，为严重和罕见疾病开发疗法。他还带来了在纳斯达克治理方面的宝贵经验，曾担任上市公司的高级管理人员和董事会成员。在加入Rallybio之前，Lieber先生是Applied Genetic Technologies Corporation（AGTC）的首席财务官，这是一家上市的基因治疗公司，在那里他领导了所有的融资工作，并监督财务、人力资源、投资者关系和IT。他还曾在Danforth Advisors、Histogenics、雷普里根、Xcellerex（已被GE Healthcare收购）和Altus Pharmaceuticals担任高级领导职务。在其职业生涯的早期，他曾在Salomon Brothers/Salomon Smith Barney和SG 高宏集团从事投资银行工作。Lieber先生目前在Salarius制药的董事会任职，同时担任审计委员会以及提名和治理委员会的成员。
Jon Lieber currently serves as Chief Financial Officer at Rallybio, a clinical stage biotechnology company developing therapies for severe and rare diseases. He also brings valuable experience in Nasdaq governance, having served as both a senior executive and board member of publicly traded companies. Prior to Rallybio, Mr. Lieber was CFO at Applied Genetic Technologies Corporation (AGTC), a publicly traded gene therapy company, where he led all capital raising efforts and oversaw finance, human resources, investor relations, and IT. He has also held senior leadership roles at Danforth Advisors, Histogenics, Repligen, Xcellerex (acquired by GE Healthcare), and Altus Pharmaceuticals. Earlier in his career, he worked in investment banking at Salomon Brothers / Salomon Smith Barney and SG Cowen. Mr. Lieber currently serves on the Board of Directors of Salarius Pharmaceuticals, where he is a member of both the Audit Committee and the Nominating and Governance Committee. - Jon Lieber目前在Rallybio担任首席财务官，这是一家临床阶段的生物技术公司，为严重和罕见疾病开发疗法。他还带来了在纳斯达克治理方面的宝贵经验，曾担任上市公司的高级管理人员和董事会成员。在加入Rallybio之前，Lieber先生是Applied Genetic Technologies Corporation（AGTC）的首席财务官，这是一家上市的基因治疗公司，在那里他领导了所有的融资工作，并监督财务、人力资源、投资者关系和IT。他还曾在Danforth Advisors、Histogenics、雷普里根、Xcellerex（已被GE Healthcare收购）和Altus Pharmaceuticals担任高级领导职务。在其职业生涯的早期，他曾在Salomon Brothers/Salomon Smith Barney和SG 高宏集团从事投资银行工作。Lieber先生目前在Salarius制药的董事会任职，同时担任审计委员会以及提名和治理委员会的成员。
- Jon Lieber currently serves as Chief Financial Officer at Rallybio, a clinical stage biotechnology company developing therapies for severe and rare diseases. He also brings valuable experience in Nasdaq governance, having served as both a senior executive and board member of publicly traded companies. Prior to Rallybio, Mr. Lieber was CFO at Applied Genetic Technologies Corporation (AGTC), a publicly traded gene therapy company, where he led all capital raising efforts and oversaw finance, human resources, investor relations, and IT. He has also held senior leadership roles at Danforth Advisors, Histogenics, Repligen, Xcellerex (acquired by GE Healthcare), and Altus Pharmaceuticals. Earlier in his career, he worked in investment banking at Salomon Brothers / Salomon Smith Barney and SG Cowen. Mr. Lieber currently serves on the Board of Directors of Salarius Pharmaceuticals, where he is a member of both the Audit Committee and the Nominating and Governance Committee.
高管简历
中英对照 | 中文 | 英文- R. Scott Areglado
R. Scott Areglado自2019年5月起担任iCAD, Inc.的首席财务官。从2011年5月到2018年12月，他担任公司副总裁和iCAD, Inc.的财务总监，从2018年12月到2019年5月，从2016年9月到11月，他担任临时首席财务官。从2005年到2010年，他担任AMICAS公司（纳斯达克上市的形象和信息管理解决方案公司，服务于医疗保健行业）的副总裁和财务总监，在那里他领导公司的财务报表编制和会计操作。他拥有超过25年的财务和会计经验，并从1990年到2007年担任注册会计师。他持有Babson College的Franklin W. Olin Graduate School of Business的工商管理硕士学位，以及the University of Massachusetts, Amherst的会计工商管理学士学位。
R. Scott Areglado serves as the CFO for MindWalk and is responsible for overseeing the financial strategy and reporting to ensure compliance with regulations, optimizing capital allocation to support growth, and providing financial leadership.Most recently, Mr. Areglado served as Chief Financial Officer of BrainsWay Ltd. (Nasdaq: BWAY), a global medical device leader in interventional psychiatry. Before joining BrainsWay, Mr. Areglado was Chief Financial Officer at iCAD, Inc. (Nasdaq: ICAD), a medical technology company specializing in AI driven cancer detection and therapy solutions. arlier in his career, Mr. Areglado held senior financial roles at AMICAS, Inc. (Nasdaq: AMCS) and several emerging growth technology companies, where he developed deep expertise in SEC reporting, M&A integration, and operational transformation. He began his career in public accounting and holds an MBA from Babson College and a BBA in Accounting from the University of Massachusetts Amherst.- R. Scott Areglado自2019年5月起担任iCAD, Inc.的首席财务官。从2011年5月到2018年12月，他担任公司副总裁和iCAD, Inc.的财务总监，从2018年12月到2019年5月，从2016年9月到11月，他担任临时首席财务官。从2005年到2010年，他担任AMICAS公司（纳斯达克上市的形象和信息管理解决方案公司，服务于医疗保健行业）的副总裁和财务总监，在那里他领导公司的财务报表编制和会计操作。他拥有超过25年的财务和会计经验，并从1990年到2007年担任注册会计师。他持有Babson College的Franklin W. Olin Graduate School of Business的工商管理硕士学位，以及the University of Massachusetts, Amherst的会计工商管理学士学位。
- R. Scott Areglado serves as the CFO for MindWalk and is responsible for overseeing the financial strategy and reporting to ensure compliance with regulations, optimizing capital allocation to support growth, and providing financial leadership.Most recently, Mr. Areglado served as Chief Financial Officer of BrainsWay Ltd. (Nasdaq: BWAY), a global medical device leader in interventional psychiatry. Before joining BrainsWay, Mr. Areglado was Chief Financial Officer at iCAD, Inc. (Nasdaq: ICAD), a medical technology company specializing in AI driven cancer detection and therapy solutions. arlier in his career, Mr. Areglado held senior financial roles at AMICAS, Inc. (Nasdaq: AMCS) and several emerging growth technology companies, where he developed deep expertise in SEC reporting, M&A integration, and operational transformation. He began his career in public accounting and holds an MBA from Babson College and a BBA in Accounting from the University of Massachusetts Amherst.
- Jennifer Bath
詹妮弗·巴斯（Jennifer Bath），在生物制药行业拥有二十年的经验，此前曾在Aldevron，LLC的执行团队任职。此前，她是全球疫苗研究所的执行董事，曾担任国际顾问，在战略规划和企业增长以及将制药公司的科学挑战转化为运营解决方案方面拥有经验丰富且经过验证的领导者。巴斯博士专注于战略增长、业务运营调整和价值创造。她拥有北达科他州立大学细胞和分子生物学博士学位。
Jennifer Bath serves as President and Chief Executive Officer of MindWalk Holdings Corp. She holds a PhD in Cellular and Molecular Biology, with a specialization in immunology and biochemistry, and has built her career at the intersection of biological science, bioinformatics, and artificial intelligence. Prior to MindWalk, Dr. Bath held a tenured Associate Professorship and founded the Concordia Global Vaccine Institute, where she directed programs to discover and validate biologics for infectious diseases. She subsequently held executive roles across the biotechnology sectors, including an executive position at Aldevron, where she led global client relations and high value target teams, translating complex scientific and commercial challenges into operational strategy for pharmaceutical and biotech worldwide. At MindWalk, Dr. Bath leads the Company's scientific and technology teams in building its integrated discovery platform, which combines LensAI, powered by HYFT technology, with advanced wet lab capabilities. Under her leadership, the Company has advanced dozens of client molecules toward the clinic and launched ReefIQ.- 詹妮弗·巴斯（Jennifer Bath），在生物制药行业拥有二十年的经验，此前曾在Aldevron，LLC的执行团队任职。此前，她是全球疫苗研究所的执行董事，曾担任国际顾问，在战略规划和企业增长以及将制药公司的科学挑战转化为运营解决方案方面拥有经验丰富且经过验证的领导者。巴斯博士专注于战略增长、业务运营调整和价值创造。她拥有北达科他州立大学细胞和分子生物学博士学位。
- Jennifer Bath serves as President and Chief Executive Officer of MindWalk Holdings Corp. She holds a PhD in Cellular and Molecular Biology, with a specialization in immunology and biochemistry, and has built her career at the intersection of biological science, bioinformatics, and artificial intelligence. Prior to MindWalk, Dr. Bath held a tenured Associate Professorship and founded the Concordia Global Vaccine Institute, where she directed programs to discover and validate biologics for infectious diseases. She subsequently held executive roles across the biotechnology sectors, including an executive position at Aldevron, where she led global client relations and high value target teams, translating complex scientific and commercial challenges into operational strategy for pharmaceutical and biotech worldwide. At MindWalk, Dr. Bath leads the Company's scientific and technology teams in building its integrated discovery platform, which combines LensAI, powered by HYFT technology, with advanced wet lab capabilities. Under her leadership, the Company has advanced dozens of client molecules toward the clinic and launched ReefIQ.
- Kari Graber
Kari Graber，担任IPA商业服务副总裁，负责在整个IPA全球公司家族中全面领导和实施项目管理计划。她在为各食品制造商开发、实施和指导实验室操作、质量保证、法规遵从性以及供应链管理计划方面拥有超过20年的经验，并在一家巴氏杀菌/灭菌技术和设备供应商担任了五年的销售和技术总监。在加入IPA之前，Graber女士曾在Aldevron LLC任职，担任其抗体服务平台的客户关系管理职务。她拥有食品科学与技术理学学士学位和微生物学辅修学位。
Kari Graber serves as the Vice President of Commercial Services for MindWalk and is responsible for the overall leadership and implementation of the Project Management program throughout MindWalk's global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers, and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining MindWalk, Ms. Graber served at Aldevron LLC, where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology and a Minor in Microbiology.- Kari Graber，担任IPA商业服务副总裁，负责在整个IPA全球公司家族中全面领导和实施项目管理计划。她在为各食品制造商开发、实施和指导实验室操作、质量保证、法规遵从性以及供应链管理计划方面拥有超过20年的经验，并在一家巴氏杀菌/灭菌技术和设备供应商担任了五年的销售和技术总监。在加入IPA之前，Graber女士曾在Aldevron LLC任职，担任其抗体服务平台的客户关系管理职务。她拥有食品科学与技术理学学士学位和微生物学辅修学位。
- Kari Graber serves as the Vice President of Commercial Services for MindWalk and is responsible for the overall leadership and implementation of the Project Management program throughout MindWalk's global family of companies. She has over 20 years of experience in developing, implementing and directing laboratory operations, quality assurance, regulatory compliance, and supply chain management programs for various food manufacturers, and spent five years as Sales and Technical Director for a pasteurization/sterilization technology and equipment supplier. Prior to joining MindWalk, Ms. Graber served at Aldevron LLC, where she held a client relations management role for their antibody services platform. She holds a Bachelor of Science in Food Science & Technology and a Minor in Microbiology.
- Thomas W. Lynch
Thomas W. Lynch，是一位卓有成就的行业领导者，拥有超过二十年的经验，专注于生物技术和软件创新的交叉领域。林奇博士在扩展全球商业组织、推出具有高影响力的产品以及推动先进软件和数据平台的市场采用方面有着良好的业绩记录。他的职业生涯涵盖技术销售、客户服务和业务发展，通过将深刻的科学理解与严格的商业执行相结合，他始终实现了增长。
Thomas W. Lynch most recently served as Director of Technical Sales & Scientific Support at Aldevron, where he built and led a new global commercial Team, aligning strategies with scientific innovation and client needs. Prior to that, as Vice President of Global Sales and Client Services, Dr. Lynch spearheaded key initiatives including the introduction of clinical mRNA manufacturing services and strategic account expansion that materially advanced Aldevron's market position. Earlier in his career, Dr. Lynch led global commercial operations at DNASTAR, overseeing sales, distribution, and technical support while successfully launching software products that advanced protein structure prediction and analysis, such as NovaFold powered by I TASSER.Dr. Lynch also serves on the Board of BioForward, Wisconsin's leading biohealth association, where he helped drive industry collaboration, education, and legislative initiatives across Wisconsin's biohealth sector.- Thomas W. Lynch，是一位卓有成就的行业领导者，拥有超过二十年的经验，专注于生物技术和软件创新的交叉领域。林奇博士在扩展全球商业组织、推出具有高影响力的产品以及推动先进软件和数据平台的市场采用方面有着良好的业绩记录。他的职业生涯涵盖技术销售、客户服务和业务发展，通过将深刻的科学理解与严格的商业执行相结合，他始终实现了增长。
- Thomas W. Lynch most recently served as Director of Technical Sales & Scientific Support at Aldevron, where he built and led a new global commercial Team, aligning strategies with scientific innovation and client needs. Prior to that, as Vice President of Global Sales and Client Services, Dr. Lynch spearheaded key initiatives including the introduction of clinical mRNA manufacturing services and strategic account expansion that materially advanced Aldevron's market position. Earlier in his career, Dr. Lynch led global commercial operations at DNASTAR, overseeing sales, distribution, and technical support while successfully launching software products that advanced protein structure prediction and analysis, such as NovaFold powered by I TASSER.Dr. Lynch also serves on the Board of BioForward, Wisconsin's leading biohealth association, where he helped drive industry collaboration, education, and legislative initiatives across Wisconsin's biohealth sector.
- Shuji Sato
Shuji Sato担任MindWalk创新解决方案副总裁，专注于持续提供高价值、技术先进的科学服务，以满足最具挑战性项目的目标。他在各种研发环境中拥有超过20年的经验，包括在众多生物技术和制药公司以及学术界指导体内和体外抗体发现和开发团队。他将自己在药物开发方面的广泛知识应用于项目的概念化和实现，并推动开发有效和创新的工作流程。Sato博士拥有塔夫茨大学分子微生物学博士学位，并在哈佛医学院接受博士后培训，在加入细胞信号技术的创新研究小组之前，曾在Bluefin Biomedicine、辉瑞和Dragonfly Therapeutics担任首席科学家和副主任职务。在他的整个研究生涯中，佐藤博士共同撰写了许多同行评审的科学文章和专利。
Shuji Sato serves as the Vice President of Innovative Solutions for MindWalk with a focus on consistently delivering high value, technologically advanced scientific services to meet the objectives of the most challenging projects. He has over 20 years of experience in various R&D settings, including directing in vivo and in vitro antibody discovery and development teams at numerous biotech and pharma as well as in academia. He applies his broad knowledge in drug development to conceptualization and realization of projects and drives development of effective and innovative workflows. Dr. Sato holds a PhD in Molecular Microbiology from Tufts University and trained as a postdoctoral fellow at Harvard Medical School, prior to joining Cell Signaling Technology's innovative research group and has held Principal Scientist and Associate Director positions at Bluefin Biomedicine, Pfizer and Dragonfly Therapeutics. Throughout his research career, Dr. Sato has co authored numerous peer reviewed scientific articles and patents.- Shuji Sato担任MindWalk创新解决方案副总裁，专注于持续提供高价值、技术先进的科学服务，以满足最具挑战性项目的目标。他在各种研发环境中拥有超过20年的经验，包括在众多生物技术和制药公司以及学术界指导体内和体外抗体发现和开发团队。他将自己在药物开发方面的广泛知识应用于项目的概念化和实现，并推动开发有效和创新的工作流程。Sato博士拥有塔夫茨大学分子微生物学博士学位，并在哈佛医学院接受博士后培训，在加入细胞信号技术的创新研究小组之前，曾在Bluefin Biomedicine、辉瑞和Dragonfly Therapeutics担任首席科学家和副主任职务。在他的整个研究生涯中，佐藤博士共同撰写了许多同行评审的科学文章和专利。
- Shuji Sato serves as the Vice President of Innovative Solutions for MindWalk with a focus on consistently delivering high value, technologically advanced scientific services to meet the objectives of the most challenging projects. He has over 20 years of experience in various R&D settings, including directing in vivo and in vitro antibody discovery and development teams at numerous biotech and pharma as well as in academia. He applies his broad knowledge in drug development to conceptualization and realization of projects and drives development of effective and innovative workflows. Dr. Sato holds a PhD in Molecular Microbiology from Tufts University and trained as a postdoctoral fellow at Harvard Medical School, prior to joining Cell Signaling Technology's innovative research group and has held Principal Scientist and Associate Director positions at Bluefin Biomedicine, Pfizer and Dragonfly Therapeutics. Throughout his research career, Dr. Sato has co authored numerous peer reviewed scientific articles and patents.